194 related articles for article (PubMed ID: 16418310)
1. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.
Schöffski P; Dumez H; Clement P; Hoeben A; Prenen H; Wolter P; Joniau S; Roskams T; Van Poppel H
Ann Oncol; 2006 Aug; 17(8):1185-96. PubMed ID: 16418310
[TBL] [Abstract][Full Text] [Related]
2. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
3. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Biró K; Küronya Z
Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
[TBL] [Abstract][Full Text] [Related]
4. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib for the treatment of renal cancer.
Strumberg D
Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Chowdhury S; Larkin JM; Gore ME
Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
[TBL] [Abstract][Full Text] [Related]
7. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
8. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
12. New treatments for renal cell carcinoma: targeted therapies.
Saylor PJ; Michaelson MD
J Natl Compr Canc Netw; 2009 Jun; 7(6):645-56. PubMed ID: 19555586
[TBL] [Abstract][Full Text] [Related]
13. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
Garcia JA; Hudes GR; Choueiri TK; Stadler WM; Wood LS; Gurtler J; Bhatia S; Joshi A; Hozak RR; Xu Y; Schwartz JD; Thompson JA
Cancer; 2014 Jun; 120(11):1647-55. PubMed ID: 24577874
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
16. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Bhargava P; Robinson MO
Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
20. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]